Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things, hear about IP waivers for coronavirus vaccines; launch records for Pfizer’s COVID-19 vaccine; new potential delivery routes for booster vaccines; newcomers in the BCMA-targeting field; and a snapshot of the current state of play in global pharma R&D.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 7 May 2021, including: possible intellectual property waivers for coronavirus vaccines; launch records for Pfizer Inc.’s COVID-19 vaccine; new potential delivery routes for booster vaccines; newcomers in the BCMA-targeting field; and a snapshot of the current state of play in global pharma R&D.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "US COVID Vaccine Patent Waiver Is Big, Symbolic Blow For Pharma, But The Fight Is Just Beginning" - Scrip, 5 May, 2021.)
(Also see "Credit Where It Is Due: Pfizer’s COVID-19 Vaccine Smashes Launch Records As Expected" - Scrip, 4 May, 2021.)
(Also see "Your Annual COVID-19 Vaccine Booster Could Be A Pill Or A Spray" - Scrip, 30 Apr, 2021.)
(Also see "With Two BCMA-Targeting Myeloma Treatments, Which Should Be First Choice?" - Scrip, 3 May, 2021.)
(Also see "The 2021 Worldwide Pharma And Biotech R&D Scene" - Scrip, 5 May, 2021.)